

Dr Henning Gädeke
c/o Dr Michael Makanga
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d’Or
1060 Brussels
Belgium

29 September 2025

**RE: Letter of endorsement in support of WANECAM 3 (101248917-1) under the
HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage call for proposal**

Dear Dr Gädeke,

In accordance with Council Regulation (EU) No. 2085/2021 of 19 November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, MMV Medicines for Malaria Venture (MMV), Route de Pré-Bois 20, Post Box 1826, CH-1215 Geneva 15, Switzerland, hereby submits an endorsement letter declaring cash and in-kind support to the **WANECAM3** (101248917-1) proposal submitted in response to the HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage call.

MMV, a partner in the WANECAM3 consortium, is a Swiss not-for-profit foundation working through a Product Development Partnership model to deliver a portfolio of accessible medicines with the power to treat, prevent and eliminate malaria. Our work to deliver novel interventions against malaria is strongly aligned with GH EDCTP3’s vision to reduce the burden of poverty-related infectious diseases in sub-Saharan Africa. By providing novel, effective, convenient, and scalable solutions, we support the acceleration of global progress towards malaria elimination, strengthen health systems, and contribute profoundly to global health security and social and economic development in LMICs. Reducing the global malaria disease burden contributes to the achievement of several Sustainable Development Goals (SDGs 3, 5 and 17). Our success is built on strong partnerships with pharmaceutical companies, academia and public health stakeholders across the world.

Our consortium, WANECAM3, builds on EDCTP2 investments in previous consortia, WANECAM and WANECAM2. The focus of WANECAM3 is on the execution of Phase 2 and Phase 3 clinical trials to evaluate novel malaria candidates with the capability to deliver single dose cure. The clinical trials proposed to take place under WANECAM3 are across a wider geographic range than previous WANECAM projects, including Mali, Burkina Faso, Gabon, Uganda, Kenya and Ethiopia and involve pharmaceutical, academic and non-profit partners from Germany, The Netherlands, UK and Switzerland. Although exceptionally challenging,

we strongly believe that the development of a single dose cure for uncomplicated malaria due to *Plasmodium falciparum* has the potential to make a huge contribution to alleviating the burden of malaria, and advancing the aim of malaria elimination and ultimately eradication. MMV will particularly contribute to two aspects of the consortium's activities.

1. MMV533 is a novel compound that has been evaluated in MMV-sponsored nonclinical and Phase 1 clinical trials, demonstrating promise to support a single dose cure candidate. If the consortium proposal is successful, MMV will work with the consortium partners to facilitate the evaluation of the compound in Novartis' Phase 2 platform study 'PLATINUM'. In so doing, **MMV will provide the drug product and make the financial contribution outlined in the table below to support trial operations.**
2. In addition, MMV has substantial experience in the conduct of clinical trials in sub-Saharan Africa and a record of translating research findings into policy and practice. Through an in-kind contribution, MMV will support the **clinical trials work package (WP3) particularly as it relates to the evaluation of MMV533 and the communication, dissemination and exploitation work package (WP6).** The estimated value of these costs is also outlined in the table below.

We estimate the total value of this cash and in-kind contribution to be € 1 835 000 as detailed in the table below:

Description of activities and contributions

Contributions for Work Package 3, clinical trials

In-kind contribution: direct personnel costs.

*To provide subject matter expertise to support the Novartis-sponsored Phase 2a study and contribute to consortium activities (Development Director, Study Physician, Clinical Scientist). MMV's staff contributions will principally support the conduct of the clinical evaluation of the MMV533 compound: milestones **3.6 to 3.10** inclusive and deliverables **3.5 to 3.8** inclusive plus those communication and dissemination activities relevant to the clinical trial (deliverables **6.4** and **6.5**).*

*Direct personnel costs relating to Phase 2a study of MMV533.
Program director 0.1 FTE, Study physician 0.1 FTE, Clinical
scientist 0.05 FTE for duration of the project.*

€192 000

Cash contribution:

*MMV's cash contribution to the project is intended to offset costs related to the Novartis-sponsored Phase 2 clinical evaluation of the MMV533 compound. These costs relate to milestones **3.6 to 3.10** inclusive and deliverables **3.5 to 3.8** inclusive.*

<i>Clinical trial supplies (drug product)</i>	75 000
<i>Central laboratory, evaluation of biomarkers, assessment of pharmacokinetics</i>	650 000
<i>Data management</i>	185 000
<i>ECGs</i>	90 000
<i>Training and QC</i>	110 000
<i>Patient costs (reagents, ECGs, clinical trial staff salaries, community outreach, fees etc.)</i>	510 000
Total	€1 620 000

Contributions for Work Package 6, communication, dissemination, exploitation

In-kind contribution: other direct costs.

*Communications consultant and associated activity costs, 0.05 FTEs for duration of project supporting communication and dissemination deliverables **6.1 to 6.5** inclusive.*

*Communications consultant and associated activity costs
(developing a communication, dissemination and exploitation plan,
communication toolkit and consortium website).*

€23 000

Thanks to EDCTP2 support, the existing WANECAM consortium has already brought together representatives from academia, the pharmaceutical industry and non-profit sectors and acts as an exemplar for Africa-Europe partnerships that drive research and innovation through sharing scientific expertise and enhancing research capacities, and support the next generation of scientific leaders for Africa. The new consortium proposed here, WANECAM3, is an important supplement to the already successful WANECAM and WANECAM2 programs. If awarded, the consortium plans to initiate at least three Phase 2 to 3 clinical trials. These will generate clinical data for a number of candidate antimalarials that will be critical

to the development of improved antimalarial treatments, particularly for children, to tackle drug resistance and drive towards elimination and ultimately eradication. WANECA3 will help address important health gaps, strengthen health systems, and reduce the socio-economic impact of infectious diseases in sub-Saharan Africa both directly by tackling malaria and indirectly through capacity strengthening and partnership building. By leveraging and expanding the existing WANECA3 network, WANECA3 will cement the legacy of the previous consortia and further build the expertise and infrastructure that have been fostered to date.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,



Dr Martin Fitchet M.D.
Chief Executive Officer